Resumen
There is a need to leverage improvement of glycemic control and user experience for the wide adoption of artificial pancreas
technology in type 1 diabetes. A major challenge in this sense is meal control, with large glycemic impact and yet too
burdensome for patients in current hybrid artificial pancreas systems due to carb counting. Consideration of human factors
into a system's design is of paramount importance for a successful technology adoption, since expectations and needs differ
from patient to patient. "Perceived usefulness" and "perceived ease of use" by the patient yields to its behavioral intention to
use the device. Systems designed to admit flexible user interactions at meals, with minimum loss of performance in the
absence of meal announcement when compared to current hybrid systems, are needed. Insulin-pramlintide systems are
identified as expected major players to achieve this objective. The starting hypothesis of this project is that parallel multipleinput
control architectures offer the required flexibility to accommodate to different levels of user interaction at meals without
detriment of glycemic control, which may involve additional control actions with important constraints due to side effects such
as pramlintide, analogously to glucagon. The overall goal of this project is to develop such new postprandial control
strategies for an artificial pancreas with flexible user interactions at mealtime to maximize perceived usefulness and ease of
use by patients. Clinical evaluation will be performed through mixed meal in-hospital and free-living ambulatory studies to
analyze postprandial performance and system usability of developments with most immediate clinical translation. In
particular, these studies will challenge the system with announced/unannounced meals, and meals with different nutritional
composition.
